Difference between revisions of "Ticagrelor (Brilinta)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
Line 9: | Line 9: | ||
*9/3/2015: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute Guide coronary syndrome (ACS) or a history of myocardial infarction (MI). | *9/3/2015: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute Guide coronary syndrome (ACS) or a history of myocardial infarction (MI). | ||
− | [[Category: | + | [[Category:Drugs]] |
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Revision as of 22:37, 13 June 2018
General information
Class/mechanism: Reversible cyclopentyl-triazolo-pyrimidine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a
History of changes in FDA indication
Note that this agent does not have a hematology-specific indication at this time.
- 7/20/2011: Initial FDA approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
- 9/3/2015: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute Guide coronary syndrome (ACS) or a history of myocardial infarction (MI).